Annovis Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 6
- Market Cap
- $119.1M
- Website
- http://www.annovisbio.com
- Introduction
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants with Early AD
- Conditions
- Early Alzheimers Disease
- Interventions
- Drug: buntanetap/posiphenDrug: Placebo
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 760
- Registration Number
- NCT06709014
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Buntanetap/PosiphenDrug: Placebo
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05686044
- Locations
- 🇺🇸
Inland Northwest Research, Spokane, Washington, United States
🇺🇸The Belinga Clinic, Fort Smith, Arkansas, United States
🇺🇸Visionary Investigators Network, Pembroke Pines, Florida, United States
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
- Conditions
- Parkinson's Disease, Idiopathic
- Interventions
- Drug: PlaceboDrug: buntanetap/posiphen
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 523
- Registration Number
- NCT05357989
- Locations
- 🇺🇸
Medical Professional Clinical Research Center, INC, Miami, Florida, United States
🇺🇸Josephson Wallack Munshower Neurology, P.C., Indianapolis, Indiana, United States
🇺🇸Ohio State University Wexner Medical Center (OSUWMC) - CarePoint Gahanna, Columbus, Ohio, United States
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
- Conditions
- Alzheimer DiseaseParkinson Disease
- Interventions
- Drug: PlaceboDrug: Posiphen
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04524351
- Locations
- 🇺🇸
Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States
🇺🇸DeLand Clinical Research Unit, DeLand, Florida, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02925650
- Locations
- 🇺🇸
UCSD Alzheimer's Disease Research Center, La Jolla, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸IU Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
- Conditions
- Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Annovis Bio Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01072812
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, San Antonio, Texas, United States